Biote Corp.
Description
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
About
CEO
Ms. Teresa S. Weber
Employees
194
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Care Facilities
MIC code
XNMS
Address
1875 W. Walnut Hill Ln #100, Irving, TX 75038, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 13, 2024 | 0.09 | 0.33 | 0.24 | 266.67% |
| Aug 9, 2024 | 0.09 | -0.15 | -0.24 | -266.67% |
| May 8, 2024 | 0.03 | -0.06 | -0.09 | -300.00% |
| Mar 13, 2024 | 0.08 | 0.18 | 0.10 | 125.00% |
| Nov 8, 2023 | 0.08 | 0.24 | 0.16 | 200.00% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 1 |
| Average estimate | — | 0.19 | — | 0.93 |
| Low estimate | — | 0.19 | — | 0.93 |
| High estimate | — | 0.19 | — | 0.93 |
| Last year EPS | — | 0.32 | — | 0.52 |
[stock_revenue_estimate]
Growth estimates
Current qtr
68.280%
Next qtr. (Mar 2025)
-41.030%
Current year
-65.810%
Next year (Dec 2025)
78.850%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 185.36M | 164.96M | 139.40M | 116.57M | 109.98M |
| Cost of revenue | 57.88M | 54.58M | 48.82M | 44.93M | 43.57M |
| Gross profit | 127.48M | 110.38M | 90.58M | 71.64M | 66.41M |
| Operating expense | |||||
| Research & development | — | — | — | — | — |
| Selling general and admin | 98.83M | 171.10M | 53.96M | 37.43M | 39.29M |
| Other operating expenses | — | 974,000 | 2.06M | 2.43M | 3.59M |
| Operating income | 28.66M | -60.72M | 34.56M | 31.78M | 23.53M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 6.36M | 4.05M | 1.67M | 2.43M | 2.08M |
| Other income expense | -22.42M | 66.48M | 17,000 | -5,000 | -65,000 |
| Pretax income | -123,000 | 1.71M | 32.91M | 29.35M | 21.38M |
| Tax provision | 2.68M | 388,000 | 286,000 | 189,000 | 93,000 |
| Net income | -2.81M | 1.32M | 32.62M | 29.16M | 21.29M |
| Basic EPS | 0.13 | -0.12 | 4.31 | 3.85 | 2.81 |
| Diluted EPS | 0.13 | -0.12 | 4.31 | 3.85 | 2.81 |
| Basic average shares | 25.71M | 8.06M | 7.57M | 7.57M | 7.57M |
| Diluted average shares | 25.71M | 8.06M | 7.57M | 7.57M | 7.57M |
| EBITDA | 31.64M | -58.49M | 35.98M | 32.91M | 24.29M |
| Net income from continuing op. | -2.81M | 1.32M | 32.62M | 29.16M | 21.29M |
| Minority interests | 6.12M | -2.29M | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 155.30M | 111.65M | 54.33M | 32.59M |
| Current assets | ||||
| Cash | — | 79.23M | 26.77M | 17.21M |
| Cash equivalents | — | — | — | — |
| Cash and cash equivalents | 89.00M | 79.23M | 26.77M | 17.21M |
| Other short term investments | — | — | — | — |
| Accounts receivable | 6.81M | 6.95M | 5.23M | 4.72M |
| Other receivables | — | — | — | — |
| Inventory | 17.31M | 11.18M | 9.62M | 4.32M |
| Prepaid assets | 7.55M | 3.82M | 1.53M | 1.57M |
| Restricted cash | — | — | — | — |
| Assets held for sale | — | — | — | — |
| Hedging assets | — | — | — | — |
| Other current assets | 308,000 | — | 3.94M | — |
| Non current assets | ||||
| Properties | — | 2.05M | 356,000 | 582,000 |
| Land and improvements | — | — | — | — |
| Machinery furniture equipment | 5.33M | 5.29M | 5.02M | 4.26M |
| Construction in progress | — | — | 705,000 | — |
| Leases | 1.51M | 1.03M | 254,000 | 254,000 |
| Accumulated depreciation | -5.61M | -4.81M | -3.65M | -2.93M |
| Goodwill | 4.97M | 5.07M | 4.55M | 2.60M |
| Investment properties | — | — | — | — |
| Financial assets | — | — | — | — |
| Intangible assets | 4.97M | 5.07M | 4.55M | 2.60M |
| Investments and advances | — | — | — | — |
| Other non current assets | 24.88M | 1.84M | — | — |
| Total liabilities | 191.84M | 169.92M | 50.21M | 49.66M |
| Current liabilities | ||||
| Accounts payable | 4.16M | 4.11M | 4.35M | 2.45M |
| Accrued expenses | 2.41M | 1.00M | 3.80M | 623,000 |
| Short term debt | 6.56M | 6.42M | 5.25M | 5.24M |
| Deferred revenue | 3.00M | 1.97M | 1.71M | 2.04M |
| Tax payable | 17,000 | 1.05M | — | — |
| Pensions | 6.07M | 4.22M | 2.21M | 1.36M |
| Other current liabilities | — | — | — | — |
| Non current liabilities | ||||
| Long term debt | 108.31M | 114.01M | 32.09M | 37.12M |
| Provision for risks and charges | — | — | — | — |
| Deferred liabilities | — | — | — | — |
| Derivative product liabilities | — | 4.10M | — | — |
| Other non current liabilities | 59.99M | 32.11M | — | — |
| Shareholders equity | ||||
| Common stock | 6,000 | 6,000 | — | — |
| Retained earnings | -29.39M | -44.46M | 4.17M | -17.05M |
| Other shareholders equity | -12,000 | -5,000 | -40,000 | -23,000 |
| Total shareholders equity | -36.55M | -58.27M | 4.13M | -17.08M |
| Additional paid in capital | — | — | — | — |
| Treasury stock | — | — | — | — |
| Minority interest | -7.15M | -13.82M | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -2.81M | 1.32M | 32.62M | 29.16M | 21.29M |
| Depreciation | 2.99M | 2.20M | 1.40M | 1.14M | 832,000 |
| Deferred Taxes | 721,000 | -743,000 | — | — | — |
| Stock-Based Compensation | 9.06M | 82.18M | — | — | — |
| Other Non-Cash Items | 11.48M | -53.61M | 448,000 | 440,000 | 336,000 |
| Accounts Receivable | -505,000 | -1.56M | -752,000 | -1.48M | -714,000 |
| Accounts Payable | -165,000 | 416,000 | 1.61M | -884,000 | 1.22M |
| Other Assets & Liabilities | -10.48M | -3.83M | -6.34M | -2.70M | 648,000 |
| Operating Cash Flow | 10.30M | 26.38M | 28.98M | 25.68M | 23.61M |
| Investing Activities | |||||
| Capital Expenditures | -359,000 | -333,000 | -1.45M | -295,000 | -704,000 |
| Net Intangibles | — | — | -2.36M | -1.10M | -968,000 |
| Net Acquisitions | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — |
| Investing Cash Flow | -359,000 | -333,000 | -1.45M | -295,000 | -704,000 |
| Financing Activities | |||||
| Long-Term Debt Issuance | — | 125.00M | — | — | 50.00M |
| Long-Term Debt Payments | -6.25M | -40.63M | -5.00M | -5.00M | -20.10M |
| Other Financing Charges | — | -797,000 | -3.94M | — | -1.11M |
| Financing Cash Flow | -14.80M | 70.71M | -20.34M | -18.32M | -30.46M |
| Other Cash Details | |||||
| End Cash Position | 89.00M | 79.23M | 26.77M | 17.21M | 10.49M |
| Income Tax Paid | 4.43M | 282,000 | 171,000 | 189,000 | 178,000 |
| Interest Paid | 9.48M | 4.43M | 1.46M | 2.49M | 1.63M |
| Free Cash Flow | 24.17M | -11.00M | 29.91M | 25.03M | 23.68M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 856,603 | 4.13M | 2.70% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 730,450 | 3.52M | 2.30% |
| Wasatch Micro-Cap Value Fund | Sep 30, 2024 | 613,010 | 2.95M | 1.93% |
| RBB Fund Inc.- Boston Partners Small Cap Value Fd II | Nov 30, 2024 | 486,915 | 2.35M | 1.53% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 342,071 | 1.65M | 1.08% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 268,262 | 1.29M | 0.84% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 222,655 | 1.07M | 0.70% |
| DFA U.S. Small Cap Series | Oct 31, 2024 | 186,142 | 897,204 | 0.59% |
| DFA U.S. Micro Cap Series | Oct 31, 2024 | 174,763 | 842,357 | 0.55% |
| World Funds Tr-Philotimo Focused Growth & Income Fd | Sep 30, 2024 | 170,200 | 820,364 | 0.54% |
Article
Biote Announces CEO Retirement and Succession Plan
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Chr.
Jan 30, 2025
Article
Is biote Corp. (BTMD) Stock Outpacing Its Medical Peers This Year?
Here is how biote Corp. (BTMD) and Doximity (DOCS) have performed compared to their sector so far this year.
Dec 18, 2024
Article
Should Value Investors Buy biote Corp. (BTMD) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Dec 16, 2024
